Technical Analysis for REGN - Regeneron Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
F 465.0 0.74% 3.43
REGN closed up 2.71 percent on Friday, March 5, 2021, on 1.15 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Up
Historical REGN trend table...

Date Alert Name Type % Chg
Slingshot Bearish Bearish Swing Setup 0.74%
Oversold Stochastic Weakness 0.74%
Oversold Stochastic Weakness 3.48%
Oversold Stochastic Weakness 4.09%
180 Bearish Setup Bearish Swing Setup 2.23%
Outside Day Range Expansion 2.23%
Oversold Stochastic Weakness 2.23%
Slingshot Bearish Bearish Swing Setup 0.42%
Lower Bollinger Band Walk Weakness 0.42%
Oversold Stochastic Weakness 0.42%
Older End-of-Day Signals for REGN ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
10 DMA Support 18 minutes ago
Down 1% 18 minutes ago
Up 3% 3 days ago
Up 1 ATR 3 days ago
Up 2% 3 days ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Regeneron Pharmaceuticals, Inc. Description

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. The company offers EYLEA injection for the treatment of neovascular age-related macular degeneration and macular edema; ZALTRAP, an injection for intravenous infusion for the treatment of patients with metastatic colorectal cancer; and ARCALYST, an injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. Its product candidates in clinical development stage consist of EYLEA for the treatment of ophthalmologic diseases; and ZALTRAP for oncology. The company's earlier stage clinical programs include various human monoclonal antibodies, such as REGN88 for rheumatoid arthritis; REGN727 for low-density lipoprotein cholesterol reduction; REGN668 for atopic dermatitis and allergic asthma; REGN421, REGN910, and REGN1400 for oncology; REGN475 for the treatment of pain; REGN846 for atopic dermatitis; and REGN1500, REGN1033, and REGN1154. It also conducts preclinical research programs in the areas of oncology and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders, inflammation and immune diseases, bone and cartilage, pain, cardiovascular diseases, and infectious diseases. The company distributes its products through third party service providers. It has strategic collaboration with Sanofi to discover, develop, and commercialize human monoclonal antibodies; and license and collaboration agreement with Bayer HealthCare for the development and commercialization of EYLEA outside the United States. The company was founded in 1988 and is headquartered in Tarrytown, New York.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Clinical Development Immunology Pain Infectious Diseases Antibodies Bone Monoclonal Antibodies Inflammation Clinical Research Disorders Macular Degeneration Ophthalmology Rheumatoid Arthritis Cardiovascular Disease Related Macular Degeneration Asthma Colorectal Cancer Vascular Diseases Cardiovascular Diseases Cholesterol Dermatitis Syndromes Macular Edema Atopic Dermatitis Related Disease Lipoprotein Related Diseases Breakthrough Therapy Cartilage Human Monoclonal Antibodies Metastatic Colorectal Cancer Angiogenesis Regeneron Allergic Asthma Immune Diseases Intravenous Infusion Muscle Disease Muscle Diseases

Is REGN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 664.64
52 Week Low 418.01
Average Volume 983,245
200-Day Moving Average 559.42
50-Day Moving Average 491.33
20-Day Moving Average 471.41
10-Day Moving Average 456.66
Average True Range 13.22
ADX 31.37
+DI 16.69
-DI 28.58
Chandelier Exit (Long, 3 ATRs ) 475.31
Chandelier Exit (Short, 3 ATRs ) 480.66
Upper Bollinger Band 504.47
Lower Bollinger Band 438.36
Percent B (%b) 0.35
BandWidth 14.02
MACD Line -13.07
MACD Signal Line -12.39
MACD Histogram -0.6853
Fundamentals Value
Market Cap 48.4 Billion
Num Shares 105 Million
EPS 27.29
Price-to-Earnings (P/E) Ratio 16.92
Price-to-Sales 6.24
Price-to-Book 5.26
PEG Ratio 0.96
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 483.30
Resistance 3 (R3) 481.63 472.71 479.68
Resistance 2 (R2) 472.71 467.17 473.55 478.47
Resistance 1 (R1) 467.14 463.75 469.92 468.81 477.27
Pivot Point 458.22 458.22 459.61 459.06 458.22
Support 1 (S1) 452.65 452.68 455.44 454.33 445.87
Support 2 (S2) 443.73 449.27 444.57 444.67
Support 3 (S3) 438.16 443.73 443.46
Support 4 (S4) 439.84